Stevanato Group Earnings Call Transcripts
Fiscal Year 2026
-
Strong growth in high-value solutions and biologics drove margin expansion and record revenues in 2025, with further gains expected in 2026. Major capacity investments in sterile cartridges and drug delivery systems support long-term growth, while new plants are set to deliver high profitability.
Fiscal Year 2025
-
Fiscal 2025 saw strong revenue and margin growth, led by high-value solutions and robust GLP-1 demand. 2026 guidance anticipates continued BDS growth, margin expansion, and high-value solutions reaching up to 48% of revenue, despite currency and engineering headwinds.
-
A leading provider of injection-related pharmaceuticals is expanding global capacity and focusing on high-value solutions for biologics and GLP-1 drugs. Revenue and EBITDA have more than doubled, with robust demand, long-term contracts, and heavy investment in R&D and integrated systems supporting growth. Several hundred molecules are being filed with clients.
-
Major CapEx investments and a shift to high-value products are driving growth, especially in biologics and GLP-1s. Policy clarity and reshoring support future U.S. expansion, while engineering segment efficiency is improving despite order timing delays.
-
Q3 revenue grew 9% year-over-year, led by high-value solutions and strong BDS segment growth. Margins expanded, guidance for 2025 was reiterated, and capacity investments continue to support robust demand in biologics and ready-to-use products.
-
The company is executing a global expansion focused on high-value solutions, with major investments in new manufacturing sites and strong multi-year customer partnerships. Financial performance is robust, driven by margin expansion and growth in high-value products, while operational improvements and market trends in biologics and drug delivery systems support a positive outlook.
-
Capacity expansion in Italy and the U.S. is on track, supported by long-term contracts and a focus on high-value products with strong gross margins. Biologics and GLP-1s drive growth, while inventory normalization and engineering improvements support future profitability. Fishers and Latina facilities are key to long-term revenue and margin expansion.
-
Q2 2025 saw 8% revenue growth, margin expansion, and strong BDS segment performance, offsetting engineering declines. High-value solutions rose to 42% of revenue, and guidance for 2025 is reiterated, with ongoing investments and market tailwinds supporting long-term growth.
-
The company is experiencing strong growth in biologics and injectables, with major capacity expansions in the U.S. and Italy supporting double-digit growth targets. Proprietary device innovation and robust demand are driving revenue, while risk management and operational optimization ensure resilience.
-
With a 75-year legacy, the group has doubled revenue in five years and is investing over EUR 1 billion to expand global capacity, focusing on high-value products for biologics and injectables. Q1 2024 showed 9% growth, and major investments are now contributing to revenue.
-
Q1 2025 saw 9% revenue growth and margin expansion, led by high-value solutions and strong BDS segment performance. Guidance for 2025 is reiterated, with tariffs expected to have a limited impact and ongoing investments in Fishers and Latina supporting future growth.
-
U.S. listing enabled benchmarking and growth, with a focus on pharma and integrated solutions. Major expansions in Indiana and Latina are progressing, driven by strong demand and multi-year contracts. High-value products and biologics are key growth areas, while operational improvements and market normalization are underway.
-
Management highlighted strong fundamentals, global expansion, and a focus on high-value solutions, with capacity investments and regulatory trends supporting future growth. Vial demand is recovering, and the company expects a return to double-digit growth and higher margins by 2027.
Fiscal Year 2024
-
Revenue grew 2% in 2024, led by high-value syringes and biologics, while vial demand declined but is recovering. 2025 guidance anticipates stronger growth in the second half, margin improvement, and continued investment in capacity expansion.
-
Destocking is progressing unevenly, with normalization expected by the end of 2025. High-value solutions are driving growth, and facility expansions in Latina and Fishers are on track to boost capacity and margins. Long-term plans target double-digit growth and higher margins by 2027.
-
Management outlined a path to double-digit revenue growth and 30% EBITDA by 2027, supported by robust biologics demand, capacity expansions, and a shift toward high-value products. Vial destocking is expected to normalize by 2025, with strong recovery in syringes and cartridges.
-
Q3 saw growth in high-value products despite vial destocking, with new plant investments progressing and long-term contracts supporting future revenue. Engineering division restructuring aims to restore margins, while regulatory and therapeutic trends drive demand for advanced solutions. 2027 targets for margin and high-value mix are reaffirmed.
-
Q3 2024 revenue rose 2% year-over-year, led by high-value solutions, but margins fell short due to higher costs in engineering and U.S. validation. Full-year Adjusted EBITDA and EPS guidance were lowered, while capacity expansions in Fishers and Latina progressed and vial destocking continued to impact results.
-
Strong growth in high-value syringes and cartridges is offsetting a temporary slowdown in vials, with recovery in major markets expected by 2025. Engineering challenges are being addressed, and margin improvements are anticipated as the product mix shifts to higher-value solutions. CapEx is set to normalize by 2027.
-
Leadership is focused on executing the industrial plan, with major investments in biologics and high-value solutions driving growth. Syringe demand offsets vial destocking, while engineering and new facilities are ramping up. Cautious optimism remains for 2025, with medium-term double-digit growth and margin targets supported by ongoing innovation and global expansion plans.
-
Q2 2024 revenue rose 2% year-over-year, led by strong BDS growth, but margins were pressured by engineering delays and ramp-up inefficiencies. Fiscal 2024 guidance was revised lower due to engineering headwinds, while high-value solutions and biologics remain key growth drivers.
-
A global leader in drug containment and delivery, the group is expanding capacity in the US and Europe to meet rising demand for high-value solutions, especially in biologics. Despite temporary market softness from vial destocking, high-margin products and innovation are driving growth.
-
Steady double-digit growth and leadership in high-value drug containment and delivery solutions position the company to capitalize on rising demand in biologics and advanced therapies. Major investments in U.S. and Italy support capacity expansion, with a focus on execution and margin growth in 2024.